Volume Spike Investor

Dendreon Corporation (NASDAQ: DNDN) is surging on news that the company has added two new directors to its board.  These are Ian Clark, the CEO of Roche’s Genentech unit, and Pedro Granadillo, a former Eli Lilly (LLY) manufacturing executive.  These are viewed as top brass to help the company transition from pre-revenue into a revenue generator when and if its PROVENGE gets approved.  At 8:43 AM EST we have seen some 270,000 shares trade hands and the stock is back up at $29.27.  The 52-week trading range is $2.55 to $30.42 and the average volume here is 2.8 million shares.  -JON C. OGG